Cargando…

Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With PIK3CA-Related Overgrowth Spectrum

Activating mutations in the PIK3CA gene, causing phosphoinositide 3-kinase (PI3K) hyperactivation, are rare causes of hypoglycemia. We report the novel use of alpelisib (a PI3K inhibitor) for the treatment of hypoketotic, hypoinsulinemic hypoglycemia in 2 children with PIK3CA-related overgrowth spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasomyont, Nat, Rutter, Meilan M, Backeljauw, Philippe F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580442/ https://www.ncbi.nlm.nih.gov/pubmed/37908459 http://dx.doi.org/10.1210/jcemcr/luad027

Ejemplares similares

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
por: Morin, Gabriel, et al.
Publicado: (2022)

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib
por: Pagliazzi, Angelica, et al.
Publicado: (2021)

Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America
por: Garneau, Alexandre P., et al.
Publicado: (2021)

Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum**
por: Keppler-Noreuil, Kim M, et al.
Publicado: (2014)

PIK3CA-related overgrowth spectrum (PROS) presenting as isolated macrodactyly
por: Krishnamurthy, Kritika, et al.
Publicado: (2023)

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
por: Parker, Victoria E. R., et al.
Publicado: (2018)

PIK3CA-related overgrowth spectrum (PROS): a rare case report
por: Kalo, Cedra, et al.
Publicado: (2023)

A Mosaic PIK3CA Mutation in a Moroccan Female: Exploring the Diagnostic Challenges of PIK3CA-Related Overgrowth Spectrum
por: Ahakoud, Mohamed, et al.
Publicado: (2023)

Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient, and Caregiver Experiences
por: Dexheimer, Joy, et al.
Publicado: (2022)

Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Koutlas, Ioannis G., et al.
Publicado: (2021)

Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Koutlas, Ioannis G., et al.
Publicado: (2020)

Segmental epidermal nevus and mucosal neuromas associated with PIK3CA-related overgrowth spectrum disorder
por: Roth, Gretchen M., et al.
Publicado: (2018)

PIK3CA-related overgrowth with an uncommon phenotype: case report
por: Rotunno, Roberta, et al.
Publicado: (2022)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Lymphangioma of the fetal neck within the PIK3CA‐related‐overgrowth spectrum (PROS): A case report
por: Scharf, Jann Lennard, et al.
Publicado: (2021)

Letter to editor: Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum
por: Maldonado, Andrés A., et al.
Publicado: (2022)

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
por: Madsen, Ralitsa R., et al.
Publicado: (2018)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
por: Yeom, Jiah, et al.
Publicado: (2023)

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang, Dwan-Ying, et al.
Publicado: (2021)

Clinical Profile of Overgrowth Syndromes Consistent with PROS (PIK3CA-Related Overgrowth Syndromes)—A Case Series
por: Mathew, Lydia, et al.
Publicado: (2020)

In vitro anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines
por: Maeda, Marika, et al.
Publicado: (2022)

PIK3CA-Related Overgrowth Syndrome (PROS) and Angiosarcoma: A Case Report
por: Weinstein, Brielle, et al.
Publicado: (2020)

Mapping the PIK3CA-related overgrowth spectrum (PROS) patient and caregiver journey using a patient-centered approach
por: Rodríguez-Laguna, Lara, et al.
Publicado: (2022)

Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms Tumor in PIK3CA-related overgrowth spectrum (PROS)
por: Waberski, Marta Biderman, et al.
Publicado: (2018)

Qualitative research with patients and caregivers of patients with PIK3CA related overgrowth spectrum: content validity of clinical outcome assessments
por: Raymond, Kimberly, et al.
Publicado: (2022)

One of the First Cases with PIK3CA-related Overgrowth Spectrum (PROS) in Saudi Arabia: A Case Report and Literature Review
por: Alsaedi, Saleem A, et al.
Publicado: (2020)

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
por: Sterba, Martin, et al.
Publicado: (2023)

Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy
por: Roy, Achira, et al.
Publicado: (2015)

Clinical Response to PI3K-α Inhibition in a Cohort of Children and Adults With PIK3CA-Related Overgrowth Spectrum Disorders
por: Raghavendran, Prashant, et al.
Publicado: (2022)

A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
por: Bayram, Ertugrul, et al.
Publicado: (2023)

Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome
por: Forde, Karina, et al.
Publicado: (2021)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
por: Donzelli, Sara, et al.
Publicado: (2022)

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
por: Ranieri, C., et al.
Publicado: (2018)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
por: Diao, Fei-Yu
Publicado: (2021)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2023)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth
por: Frisk, Sofia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mdvdjcm8dpjcq5d0chpmd58pgi